JP2018518990A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018518990A5 JP2018518990A5 JP2018517487A JP2018517487A JP2018518990A5 JP 2018518990 A5 JP2018518990 A5 JP 2018518990A5 JP 2018517487 A JP2018517487 A JP 2018517487A JP 2018517487 A JP2018517487 A JP 2018517487A JP 2018518990 A5 JP2018518990 A5 JP 2018518990A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- nucleic acid
- polypeptide
- acid molecule
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022044885A JP7460675B2 (ja) | 2015-06-19 | 2022-03-22 | Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用 |
| JP2024044396A JP2024073636A (ja) | 2015-06-19 | 2024-03-21 | Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15172913.4 | 2015-06-19 | ||
| EP15172913 | 2015-06-19 | ||
| PCT/EP2016/064195 WO2016203048A1 (en) | 2015-06-19 | 2016-06-20 | Pd-1-cd28 fusion proteins and their use in medicine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022044885A Division JP7460675B2 (ja) | 2015-06-19 | 2022-03-22 | Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018518990A JP2018518990A (ja) | 2018-07-19 |
| JP2018518990A5 true JP2018518990A5 (enExample) | 2019-06-06 |
| JP7085988B2 JP7085988B2 (ja) | 2022-06-17 |
Family
ID=53476720
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517487A Active JP7085988B2 (ja) | 2015-06-19 | 2016-06-20 | Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用 |
| JP2022044885A Active JP7460675B2 (ja) | 2015-06-19 | 2022-03-22 | Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用 |
| JP2024044396A Pending JP2024073636A (ja) | 2015-06-19 | 2024-03-21 | Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022044885A Active JP7460675B2 (ja) | 2015-06-19 | 2022-03-22 | Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用 |
| JP2024044396A Pending JP2024073636A (ja) | 2015-06-19 | 2024-03-21 | Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11192935B2 (enExample) |
| EP (3) | EP3310805B1 (enExample) |
| JP (3) | JP7085988B2 (enExample) |
| CN (3) | CN115925971A (enExample) |
| AU (1) | AU2016277883B2 (enExample) |
| CA (1) | CA2989949A1 (enExample) |
| DK (2) | DK3909972T5 (enExample) |
| ES (2) | ES2976647T3 (enExample) |
| FI (1) | FI3909972T3 (enExample) |
| HU (1) | HUE054201T2 (enExample) |
| PL (1) | PL3310805T3 (enExample) |
| PT (1) | PT3310805T (enExample) |
| WO (1) | WO2016203048A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107531805A (zh) | 2015-03-05 | 2018-01-02 | 弗雷德哈钦森癌症研究中心 | 免疫调节融合蛋白及其用途 |
| KR20180029201A (ko) | 2015-05-18 | 2018-03-20 | 티씨알2 테라퓨틱스 인크. | 융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법 |
| PT3310805T (pt) * | 2015-06-19 | 2021-05-19 | Kobold Sebastian | Proteínas de fusão pd-1-cd28 e a sua utilização em medicina |
| HK1255637A1 (zh) * | 2015-06-29 | 2019-08-23 | The Johns Hopkins University | 免疫检查点嵌合受体疗法 |
| CN105331585A (zh) * | 2015-11-13 | 2016-02-17 | 科济生物医药（上海）有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| EP4286522A3 (en) * | 2016-03-23 | 2024-02-28 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of pd-1 and 4-1bb |
| CN107523545A (zh) * | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达抗体的杀伤性细胞及其用途 |
| EP3478722A1 (en) * | 2016-06-30 | 2019-05-08 | F. Hoffmann-La Roche AG | Improved adoptive t-cell therapy |
| WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| IL302917A (en) | 2016-10-07 | 2023-07-01 | Tcr2 Therapeutics Inc | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| JP7291396B2 (ja) | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| WO2018119298A1 (en) * | 2016-12-21 | 2018-06-28 | TCR2 Therapeutics Inc. | Engineered t cells for the treatment of cancer |
| EP4043485A1 (en) * | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
| EP3595706A1 (en) | 2017-03-17 | 2020-01-22 | Fred Hutchinson Cancer Research Center | Immunomodulatory fusion proteins and uses thereof |
| AU2019231205A1 (en) * | 2018-03-06 | 2020-09-24 | The Trustees Of The University Of Pennsylvania | Prostate-specific membrane antigen cars and methods of use thereof |
| CN108727504B (zh) * | 2018-04-16 | 2021-08-27 | 泉州向日葵生物科技有限公司 | 一种ifn与抗pd-l1抗体的融合蛋白及其应用 |
| CN111606999B (zh) * | 2019-02-26 | 2022-09-06 | 南京惟亚德生物医药有限公司 | 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用 |
| TW202042824A (zh) * | 2019-03-27 | 2020-12-01 | 賓夕法尼亞大學董事會 | Tn-MUC1嵌合抗原受體（CAR）T細胞療法 |
| EP3999079A4 (en) * | 2019-07-19 | 2024-04-03 | Memorial Sloan Kettering Cancer Center | Fusion polypeptide for immunotherapy |
| CN113832114A (zh) * | 2020-06-23 | 2021-12-24 | 南京大学 | 一种新型溶瘤腺病毒EM/VSV-G Ad5-P及其在制备抗肿瘤药物中的应用 |
| CN113832111A (zh) * | 2020-06-23 | 2021-12-24 | 南京大学 | 一种类外泌体技术用于制备新型溶瘤病毒的方法 |
| CA3211402A1 (en) * | 2021-03-10 | 2022-09-15 | Moshe ELKABETS | Reporter cells expressing chimeric polypeptides for use in determining presence and or activity of immune checkpoint molecules |
| CN120988097A (zh) * | 2021-04-11 | 2025-11-21 | 中国科学院分子细胞科学卓越创新中心 | 一种pd1变体及其用途 |
| WO2022246053A2 (en) * | 2021-05-20 | 2022-11-24 | Achelois Biopharma, Inc. | Immune checkpoint multivalent particles compositions and methods of use |
| WO2023235479A1 (en) * | 2022-06-02 | 2023-12-07 | TCR2 Therapeutics Inc. | Compositions and methods for treating cancer |
| EP4619424A2 (en) * | 2022-11-14 | 2025-09-24 | Achelois Biopharma, Inc. | Immune checkpoint multivalent particles compositions and methods of use |
| WO2025212859A1 (en) * | 2024-04-03 | 2025-10-09 | Solid Biosciences, Inc. | Methods and constructs for increasing solid organ transplant survival |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19822115B4 (de) | 1998-05-08 | 2004-04-08 | Heinrich-Pette-Institut | Retrovirale Gentransfervektoren |
| JP5276846B2 (ja) | 2005-09-13 | 2013-08-28 | 国立大学法人三重大学 | Ｔ細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞 |
| WO2010012829A1 (en) | 2008-07-31 | 2010-02-04 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Her2/neu specific t cell receptors |
| ZA200807283B (en) | 2008-08-22 | 2009-10-28 | Mechlift Invest Pty Ltd | Data unit for a bin lifting device |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CN107188969B (zh) | 2011-04-08 | 2021-08-27 | 美国卫生和人力服务部 | 抗-表皮生长因子受体变体iii嵌合抗原受体及其用于治疗癌症的用途 |
| PE20141520A1 (es) | 2011-07-29 | 2014-11-17 | Univ Pennsylvania | Receptores coestimuladores de cambio |
| WO2013059593A1 (en) | 2011-10-20 | 2013-04-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd22 chimeric antigen receptors |
| KR101471647B1 (ko) | 2011-10-26 | 2014-12-11 | 국립암센터 | 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물 |
| WO2013062365A2 (ko) | 2011-10-26 | 2013-05-02 | 국립암센터 | 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물 |
| CA3209571A1 (en) | 2012-03-23 | 2013-09-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| WO2013154760A1 (en) | 2012-04-11 | 2013-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| EP3039040B1 (en) | 2013-08-26 | 2021-12-22 | Hinrich Abken | Anti cd30 chimeric antigen receptor and its use |
| BR112017011771A2 (pt) | 2014-12-02 | 2018-07-10 | Prospect Chartercare Rwmc Llc | métodos e composições para o tratamento de câncer |
| PT3310805T (pt) | 2015-06-19 | 2021-05-19 | Kobold Sebastian | Proteínas de fusão pd-1-cd28 e a sua utilização em medicina |
| WO2019051128A1 (en) | 2017-09-06 | 2019-03-14 | Fred Hutchinson Cancer Research Center | SPECIFIC STREP LABEL CHIMERIC RECEPTORS AND USES THEREOF |
| CN115418362B (zh) * | 2019-12-02 | 2025-06-13 | 吉林凯莱英医药化学有限公司 | 共固定化酶、其制备方法及其应用 |
-
2016
- 2016-06-20 PT PT167368026T patent/PT3310805T/pt unknown
- 2016-06-20 JP JP2018517487A patent/JP7085988B2/ja active Active
- 2016-06-20 CA CA2989949A patent/CA2989949A1/en active Pending
- 2016-06-20 DK DK21155542.0T patent/DK3909972T5/da active
- 2016-06-20 EP EP16736802.6A patent/EP3310805B1/en active Active
- 2016-06-20 EP EP21155542.0A patent/EP3909972B1/en active Active
- 2016-06-20 CN CN202210854297.2A patent/CN115925971A/zh active Pending
- 2016-06-20 PL PL16736802T patent/PL3310805T3/pl unknown
- 2016-06-20 FI FIEP21155542.0T patent/FI3909972T3/fi active
- 2016-06-20 AU AU2016277883A patent/AU2016277883B2/en active Active
- 2016-06-20 US US15/737,877 patent/US11192935B2/en active Active
- 2016-06-20 DK DK16736802.6T patent/DK3310805T3/da active
- 2016-06-20 ES ES21155542T patent/ES2976647T3/es active Active
- 2016-06-20 ES ES16736802T patent/ES2870174T3/es active Active
- 2016-06-20 WO PCT/EP2016/064195 patent/WO2016203048A1/en not_active Ceased
- 2016-06-20 CN CN201680048221.3A patent/CN108026151B/zh active Active
- 2016-06-20 CN CN202210834160.0A patent/CN115927474A/zh active Pending
- 2016-06-20 HU HUE16736802A patent/HUE054201T2/hu unknown
- 2016-06-20 EP EP24156660.3A patent/EP4349854A3/en active Pending
-
2021
- 2021-10-29 US US17/515,250 patent/US20220169699A1/en active Pending
-
2022
- 2022-03-22 JP JP2022044885A patent/JP7460675B2/ja active Active
-
2024
- 2024-03-21 JP JP2024044396A patent/JP2024073636A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018518990A5 (enExample) | ||
| JP7452880B2 (ja) | Ｓｓｘ２抗原を識別するｔ細胞受容体 | |
| US20210363258A1 (en) | Hpv-specific binding molecules | |
| CN106414748B (zh) | 嵌合抗原受体及制备方法 | |
| JP7146397B2 (ja) | 改変γδＴ細胞 | |
| EP3024468B1 (en) | T cell receptors | |
| JP2017537627A5 (enExample) | ||
| CN106478809B (zh) | 识别prame抗原短肽的tcr | |
| JP2019516663A5 (enExample) | ||
| CN110177808A (zh) | 针对axl或ror2的嵌合抗原受体及其使用方法 | |
| JP2017535292A5 (enExample) | ||
| FI3909972T3 (fi) | Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä | |
| JP2016534717A5 (enExample) | ||
| BR112021008133A2 (pt) | Métodos para seleção e estimulação de células e aparelhos para os mesmos | |
| JP2018504145A5 (enExample) | ||
| JP2017538401A5 (enExample) | ||
| JP7429455B2 (ja) | Ａｆｐ抗原を識別するｔ細胞受容体 | |
| JP2019512251A5 (enExample) | ||
| US20250283037A1 (en) | Methods for stimulating and transducing t cells | |
| CN108085340A (zh) | 一种同时表达靶向cd19和cd20的car与pd1-cd28嵌合受体的慢病毒载体 | |
| US20250237628A1 (en) | Cell selection and/or stimulation devices and methods of use | |
| KR20230013257A (ko) | 종양 미세환경의 역전을 위한 융합 단백질 및 이의 응용 | |
| KR20230012465A (ko) | 암 및 관련 악성 종양을 치료하기 위해 t 세포를 확장하는 방법 | |
| JP2019520038A5 (enExample) | ||
| CN111848818A (zh) | 一种增强型免疫细胞及其应用 |